Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker FATE
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Kamal Adawi Chief Financial Officer | FATE Fate Therapeutics, Inc. | Sale | 6,582 | $2.05 | $13.5K Sale | Form 4 ↗ |
| Aug 4, 2026 | Cindy Tahl See Remarks | FATE Fate Therapeutics, Inc. | Sale | 38,800 | $2.46 | $95.4K Sale | Form 4 ↗ |
| Aug 4, 2026 | Bahram Valamehr President and CEO, Director | FATE Fate Therapeutics, Inc. | Sale | 43,947 | $2.46 | $108.1K Sale | Form 4 ↗ |
| May 20, 2026 | Cindy Tahl See Remarks | FATE Fate Therapeutics, Inc. | Sale | 25,590 | $1.88 | $48.1K Sale | Form 4 ↗ |
| May 20, 2026 | Bahram Valamehr President and CEO, Director | FATE Fate Therapeutics, Inc. | Sale | 28,946 | $1.88 | $54.4K Sale | Form 4 ↗ |
| Jan 9, 2026 | Cindy Tahl See Remarks | FATE Fate Therapeutics, Inc. | Sale | 10,589 | $1.06 | $11.2K Sale | Form 4 ↗ |
| Jan 9, 2026 | Bahram Valamehr President and CEO, Director | FATE Fate Therapeutics, Inc. | Sale | 5,190 | $1.07 | $5,553 Sale | Form 4 ↗ |
| Aug 4, 2025 | Cindy Tahl See Remarks | FATE Fate Therapeutics, Inc. | Sale | 9,037 | $1.06 | $9,579 Sale | Form 4 ↗ |
| Aug 4, 2025 | Bahram Valamehr President and CEO, Director | FATE Fate Therapeutics, Inc. | Sale | 14,466 | $1.06 | $15.3K Sale | Form 4 ↗ |
| Jan 10, 2025 | Jerome Charles Bressi See Remarks | FATE Fate Therapeutics, Inc. | Sale | 5,980 | $1.55 | $9,269 Sale | Form 4 ↗ |
| Jan 10, 2025 | Cindy Tahl See Remarks | FATE Fate Therapeutics, Inc. | Sale | 5,654 | $1.55 | $8,764 Sale | Form 4 ↗ |
| Jan 10, 2025 | Bahram Valamehr President and CEO, Director | FATE Fate Therapeutics, Inc. | Sale | 8,705 | $1.54 | $13.4K Sale | Form 4 ↗ |
| Dec 20, 2024 | Jeremy Green Director, 10% owner | FATE Fate Therapeutics, Inc. | Buy | 397,964 | $1.68 | $668.6K Buy | Form 4 ↗ |
| Dec 20, 2024 | Jeremy Green Director, 10% owner | FATE Fate Therapeutics, Inc. | Sale | 341,633 | $1.68 | $573.9K Sale | Form 4 ↗ |
14 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances